Recombinant multi-species ANGPTL8/Betatrophin protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ANGPTL8/Betatrophin protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Predicted to enable hormone activity. Involved in regulation of lipid metabolic process and triglyceride homeostasis. Acts upstream of or within positive regulation of protein processing and regulation of lipoprotein metabolic process. Located in extracellular region. [provided by Alliance of Genome Resources, Apr 2022]
The Alternative Names of target: ANGPTL8,Angiopoietin-like protein 8,Angptl8,Betatrophin,C19orf80,C7H19orf80,EG624219,Gm6484,Lipasin,PRO1185,PVPA599,RIFL,Refeeding-induced fat and liver protein,Rifl,TD26
Go
to ANGPTL8/Betatrophin products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-SE0614-Ag-1/ GM-Tg-hg-SE0614-Ag-2 | Human ANGPTL8/Betatrophin protein | Human |
| GM-Tg-rg-SE0614-Ag-1/ GM-Tg-rg-SE0614-Ag-2 | Rat ANGPTL8/Betatrophin protein | Rat |
| GM-Tg-mg-SE0614-Ag-1/ GM-Tg-mg-SE0614-Ag-2 | Mouse ANGPTL8/Betatrophin protein | Mouse |
| GM-Tg-cynog-SE0614-Ag-1/ GM-Tg-cynog-SE0614-Ag-2 | Cynomolgus/Rhesus macaque ANGPTL8/Betatrophin protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-SE0614-Ag-1/ GM-Tg-felg-SE0614-Ag-2 | Feline ANGPTL8/Betatrophin protein | Feline |
| GM-Tg-cang-SE0614-Ag-1/ GM-Tg-cang-SE0614-Ag-2 | Canine ANGPTL8/Betatrophin protein | Canine |
| GM-Tg-bovg-SE0614-Ag-1/ GM-Tg-bovg-SE0614-Ag-2 | Bovine ANGPTL8/Betatrophin protein | Bovine |
| GM-Tg-equg-SE0614-Ag-1/ GM-Tg-equg-SE0614-Ag-2 | Equine ANGPTL8/Betatrophin protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-SE0614-Ag-1/ GM-Tg-hg-SE0614-Ag-2;
GM-Tg-rg-SE0614-Ag-1/ GM-Tg-rg-SE0614-Ag-2;
GM-Tg-mg-SE0614-Ag-1/ GM-Tg-mg-SE0614-Ag-2; GM-Tg-cynog-SE0614-Ag-1/ GM-Tg-cynog-SE0614-Ag-2; GM-Tg-felg-SE0614-Ag-1/ GM-Tg-felg-SE0614-Ag-2; GM-Tg-cang-SE0614-Ag-1/ GM-Tg-cang-SE0614-Ag-2; GM-Tg-bovg-SE0614-Ag-1/ GM-Tg-bovg-SE0614-Ag-2; GM-Tg-equg-SE0614-Ag-1/ GM-Tg-equg-SE0614-Ag-2 |
| Products Name | ANGPTL8/Betatrophin protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | ANGPTL8/Betatrophin |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ANGPTL8/Betatrophin protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.